Scott Farris
Psychiatric/Mental Health, Adult · Knoxville, TNNPI 1982863924
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $638 and has fallen 85.1% since, to $95 in 2024.
Across 110 payments — averaging $13.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$340
- Otsuka America Pharmaceutical, Inc.$222
- Alkermes, Inc.$201
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$180
- Lundbeck LLC$137
- Indivior Inc.$121
- plus $238 from 4 others
What the payments were for
- Food & beverage$1,39297%
- Education$473%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 42 | $340 |
| Otsuka America Pharmaceutical, Inc. | 17 | $222 |
| Alkermes, Inc. | 11 | $201 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $180 |
| Lundbeck LLC | 9 | $137 |
| Indivior Inc. | 9 | $121 |
| AbbVie | 7 | $118 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Sunovion Pharmaceuticals Inc. | 2 | $38 |
| Axsome Therapeutics, Inc. | 1 | $30 |
How this compares
Too few psychiatric/mental health, adult providers in Tennesseeto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Divalproex Sodium ErDivalproex Sodium | 16 | $503 |
| Aripiprazole | 15 | $302 |
| Risperidone | 27 | $286 |
| Olanzapine | 12 | $255 |
| Quetiapine Fumarate | 11 | $160 |
| Trazodone Hcl | 26 | $145 |
| Sertraline Hcl | 13 | $56 |
| Escitalopram Oxalate | 11 | $45 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health, adult in Knoxville
- Charlotte TunnellKnoxville$285
- Vicki ParisJackson$3K
- Jennifer BettsNashville$3K
- Susan SwansonNashville$581
- Clayton MarrsChattanooga$465
- Stephen HaileJohnson City$343
- Will ColtharpFranklin$343
- Anita WaidMemphis$185
- Brian BrownJackson$111
- Wendy WilsonNashville$72
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.